Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1

被引:6
作者
Tayshetye, Pritam [1 ]
Friday, Andrew J. [2 ]
Omstead, Ashten N. [3 ]
Verma, Tanvi [4 ]
Miller, Stacey [4 ]
Zheng, Ping [3 ]
Jani, Prashant [5 ]
Zaidi, Ali [3 ]
Finley, Gene [2 ]
机构
[1] Allegheny Hlth Network, Dept Hematol Oncol, Pittsburgh, PA 15212 USA
[2] Allegheny Gen Hosp, Dept Med Oncol, Pittsburgh, PA 15212 USA
[3] Allegheny Hlth Network, Esophageal & Lung Inst, Pittsburgh, PA 15212 USA
[4] Allegheny Hlth Network, Dept Pathol & Lab Med, Pittsburgh, PA 15212 USA
[5] Northeast Canc Ctr, Hematol & Oncol, Sudbury, ON P3E 5J1, Canada
关键词
rectal cancer; chemoradiation; tumor microenvironment; neoadjuvant; biomarker; immunotherapy; INDOLEAMINE 2,3-DIOXYGENASE; IMMUNE; CELLS; PROGRESSION; PATIENT; GAMMA;
D O I
10.3390/cancers15010276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Localized rectal cancer is currently managed with neoadjuvant therapy before surgery which includes concurrent chemoradiation therapy alone or a total neoadjuvant therapy approach which involves chemotherapy and concurrent chemoradiation sequentially. These strategies are changing, and optimal management of rectal cancer continues to evolve. Immunotherapy has entered the treatment paradigm in advanced rectal cancer for patients with microsatellite instability. A role for immunotherapy for early-stage disease has yet to be established. Clinical trials in rectal cancer incorporating immunotherapy in the neoadjuvant settings are underway however better understanding of the tumor microenvironment and targeting specific biomarkers may be more efficacious. In this paper, we report on rectal cancer tumor microenvironment changes following neoadjuvant chemoradiation. Identifying changes in biomarker expression within the tumor microenvironment may be predictive of better outcomes, improved response to immunotherapy and may also identify new targets which could lead to targeted therapeutic drug development. Background: In locally advanced rectal cancer treatment, neoadjuvant concurrent chemoradiation therapy (cCRT) is the standard of care. The tumor microenvironment (TME) is a complex entity comprising of tumor cells, immune cells and surrounding stroma and is closely associated with tumor growth and survival, response to antitumor therapies and also resistance to treatment. We aimed to assess the change in biomarkers associated with TME following standard neoadjuvant cCRT in rectal cancer. Methods: We accessed archival tissue from rectal cancer patients treated with neoadjuvant cCRT at Allegheny Health Network (AHN) facilities over the past 14 years. Pretreatment and post-treatment biopsies were assayed for PD-L1, CD8+ T-cells, CXCL9, TIM-3, IDO-1, IFN-G, IL17RE, LAG-3, and OX40 in 41 patients. Results: We found statistically significant upregulation in multiple biomarkers namely CD8, IL17RE, LAG3 and OX40 post neoadjuvant cCRT and a trend towards upregulation, although not statistically significant, in biomarkers PD-L1, CXCL9, TIM-3, IDO-1 and IFN-G expression. Conclusions: This provides a glimpse into the TME before and after neoadjuvant cCRT. We suggest that the biomarkers noted to be upregulated could be used for designing appropriate clinical trials and development of therapeutic targeted drug therapy in an effort to achieve better response to neoadjuvant therapy, increasing clinical and pathological complete response rates and improved overall outcomes.
引用
收藏
页数:9
相关论文
共 43 条
[1]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[2]   Tumor microenvironment complexity and therapeutic implications at a glance [J].
Baghba, Roghayyeh ;
Roshangar, Leila ;
Jahanban-Esfahlan, Rana ;
Seidi, Khaled ;
Ebrahimi-Kalan, Abbas ;
Jaymand, Mehdi ;
Kolahian, Saeed ;
Javaheri, Tahereh ;
Zare, Peyman .
CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)
[3]   Coinhibitory Pathways in Immunotherapy for Cancer [J].
Baumeister, Susanne H. ;
Freeman, Gordon J. ;
Dranoff, Glenn ;
Sharpe, Arlene H. .
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34, 2016, 34 :539-573
[4]   PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer [J].
Cercek, Andrea ;
Lumish, Melissa ;
Sinopoli, Jenna ;
Weiss, Jill ;
Shia, Jinru ;
Lamendola-Essel, Michelle ;
El Dika, Imane H. ;
Segal, Neil ;
Shcherba, Marina ;
Sugarman, Ryan ;
Stadler, Zsofia ;
Yaeger, Rona ;
Smith, J. Joshua ;
Rousseau, Benoit ;
Argiles, Guillem ;
Patel, Miteshkumar ;
Desai, Avni ;
Saltz, Leonard B. ;
Widmar, Maria ;
Iyer, Krishna ;
Zhang, Janie ;
Gianino, Nicole ;
Crane, Christopher ;
Romesser, Paul B. ;
Pappou, Emmanouil P. ;
Paty, Philip ;
Garcia-Aguilar, Julio ;
Gonen, Mithat ;
Gollub, Marc ;
Weiser, Martin R. ;
Schalper, Kurt A. ;
Diaz, Luis A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (25) :2363-2376
[5]   Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer [J].
Cercek, Andrea ;
Roxburgh, Campbell S. D. ;
Strombom, Paul ;
Smith, J. Joshua ;
Temple, Larissa K. F. ;
Nash, Garrett M. ;
Guillem, Jose G. ;
Paty, Philip B. ;
Yaeger, Rona ;
Stadler, Zsofia K. ;
Seier, Kenneth ;
Gonen, Mithat ;
Segal, Neil H. ;
Reidy, Diane L. ;
Varghese, Anna ;
Shia, Jinru ;
Vakiani, Efsevia ;
Wu, Abraham J. ;
Crane, Christopher H. ;
Gollub, Marc J. ;
Garcia-Aguilar, Julio ;
Saltz, Leonard B. ;
Weiser, Martin R. .
JAMA ONCOLOGY, 2018, 4 (06)
[6]   Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer [J].
Chaput, N. ;
Svrcek, M. ;
Auperin, A. ;
Locher, C. ;
Drusch, F. ;
Malka, D. ;
Taieb, J. ;
Goere, D. ;
Ducreux, M. ;
Boige, V. .
BRITISH JOURNAL OF CANCER, 2013, 109 (04) :1013-1022
[7]   Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells [J].
Chung, David J. ;
Rossi, Marco ;
Romano, Emanuela ;
Ghith, Jennifer ;
Yuan, Jianda ;
Munn, David H. ;
Young, James W. .
BLOOD, 2009, 114 (03) :555-563
[8]  
Croft M., 2013, Regulation of T Cell Immunity by OX40 and OX40L
[9]   High Frequency of CD8 Positive Lymphocyte Infiltration Correlates with Lack of Lymph Node Involvement in Early Rectal Cancer [J].
Daester, Silvio ;
Eppenberger-Castori, Serenella ;
Hirt, Christian ;
Zlobec, Inti ;
Delko, Tarik ;
Nebiker, Christian A. ;
Soysal, Savas D. ;
Amicarella, Francesca ;
Iezzi, Giandomenica ;
Sconocchia, Giuseppe ;
Heberer, Michael ;
Lugli, Alessandro ;
Spagnoli, Giulio C. ;
Kettelhack, Christoph ;
Terracciano, Luigi ;
Oertli, Daniel ;
von Holzen, Urs ;
Tornillo, Luigi ;
Droeser, Raoul A. .
DISEASE MARKERS, 2014, 2014 :1-7
[10]   CXCL9: evidence and contradictions for its role in tumor progression [J].
Ding, Qiang ;
Lu, Panpan ;
Xia, Yujia ;
Ding, Shuping ;
Fan, Yuhui ;
Li, Xin ;
Han, Ping ;
Liu, Jingmei ;
Tian, Dean ;
Liu, Mei .
CANCER MEDICINE, 2016, 5 (11) :3246-3259